Cosentyx (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹ Approval marks ...
Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed I...
Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patients First Breakthrough Therapy Design...
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phas...
Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the t...
The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on da...
ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor ago...
Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable ...
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can pote...
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerativ...
IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy so...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for t...
Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worl...
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement...
© 2026 Biopharma Boardroom. All Rights Reserved.